Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2012 April;60(2) > Minerva Cardioangiologica 2012 April;60(2):227-36

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

REVIEWS   

Minerva Cardioangiologica 2012 April;60(2):227-36

Copyright © 2012 EDIZIONI MINERVA MEDICA

language: English

Cardiovascular adverse reactions after the administration of recombinant human erythropoietin: light and shade

Berardi D., Agati L.

Department of Cardiology, “Sapienza” University, Rome, Italy


PDF


From the trials published till now, it is clear that the most important and frequent adverse reactions related to the treatment with recombinant human erythropoietin (rHuEpo) are thrombovascular accidents and systemic hypertension. Only on very rare occasions cephalea and epileptic fits may occur. Even if these adverse reactions are so precisely defined, there is no evident interpretation of the biological and pathophysiological mechanisms that sustain these events. This work intends to describe the state of the art in the international literature in order to enable the reader to understand the real risks of rHuEpo administration.

top of page